Study of the transcriptome in giant cell tumor of bone and its correlation with prognosis

• Grant number: 13/26810-9
• Support Opportunities: Scholarships abroad - Research
• Start date: August 01, 2014
• End date: July 31, 2015
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Maurício Etchebehere
• Grantee: Maurício Etchebehere
• Host Investigator: Valerae O. Lewis
• Host Institution: Faculdade de Ciências Médicas (FCM). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Institution abroad: University of Texas MD Anderson Cancer Center (MD Anderson), United States

Abstract

Although benign giant cell tumor of bone (TGC) is locally aggressive and can cause serious functional problems. At least 10% of patients have local recurrence and 2% had pulmonary implants. There are no reliable methods to detect which patients are at increased risk for local recurrence or pulmonary implants. New sequencing technologies (next generation sequencing-NGS) are fast and cheap methods that offer opportunity to achieve massive parallel data. This allows, among other approaches, to accurately determine which genes are differentially expressed. So far there are no studies that have used this technology to examine the transcriptome in GCT. Objectives: The purpose of this study is to investigate the giant cell tumors of bone transcriptome, determine key genes with differential expression and to correlate these findings with the presence of recurrence and lung implants. Methods: The study will be conducted at The University of Texas MD Anderson Cancer Center at Houston, United States. This is one of the largest services dedicated to the cancer care in the United States and the World. TGC samples from patients similarly treated will be selected. Five patients free of disease will be selected and five patients who presented recurrences or pulmonary metastases. The investigation of the transcriptome in the samples of TGC will be performed using NGS. The data will interpreted by bioinformatics analysis and the differentially expressed genes belonging to the relevant cellular pathways will be selected for validation in a larger sample of patients through Real time PCR using the TaqMan system. Results: the expectancy is to find differentially expressed genes that may influence the aggressiveness of GCT. The study of these genes may lead to the production of immunohistochemical markers to identify more aggressive tumors using biopsy samples. This information can lead the physician to perform more appropriate treatments for each patient. (AU)